Hannedouche T, Albouze G, Chauveau P, Lacour B, Jungers P
Département de Néphrologie et Biochimie A, Hôpital Necker, Paris, France.
Am J Kidney Dis. 1993 May;21(5 Suppl 2):131-7. doi: 10.1016/0272-6386(93)70104-7.
The potential role of blood pressure and antihypertensive treatment on the progression of advanced chronic renal failure was analyzed in 223 adult patients (126 males) with well-defined primary chronic renal diseases (glomerulonephritis, n = 73; angionephrosclerosis, n = 24; interstitial nephritis, n = 61; polycystic kidney disease, n = 52, Alport's syndrome, n = 13). Effect of average mean arterial pressure (MAP) obtained during follow-up, antihypertensive treatment (normotensive, conventional antihypertensive treatment, angiotensin-converting enzyme inhibitors [ACEI]), gender, type of the nephropathy, age, body mass index, and protein intake were analyzed using a multivariate analysis of variance. Mean arterial pressure was significantly and independently correlated with duration (r = -0.40, P < 0.0001) and slope of creatinine clearance (delta Ccr; r = 0.32, P < 0.0001). Mean arterial pressure and antihypertensive treatment could predict 25% of the variation in duration. Gender, type of the nephropathy, and MAP were able to predict 30% of the variation in delta Ccr. When analyzing results by type of nephropathy, MAP was significantly and inversely correlated with duration in glomerulonephritis (r = 0.29, P < 0.05), and positively with delta Ccr in angionephrosclerosis and interstitial nephritis (r = 0.49, P < 0.05 and r = 0.36, P < 0.01, respectively). In each type of nephropathy, conventional antihypertensive treatment and ACEI had grossly similar effects upon duration and slope except. In conclusion, blood pressure level is an important contributor to progression of chronic renal failure but its effect was more evident in angionephrosclerosis and interstitial nephritis at the extreme values of blood pressure distribution.(ABSTRACT TRUNCATED AT 250 WORDS)
对223例患有明确原发性慢性肾病(肾小球肾炎,n = 73;肾血管硬化症,n = 24;间质性肾炎,n = 61;多囊肾病,n = 52;奥尔波特综合征,n = 13)的成年患者(126例男性)分析了血压及抗高血压治疗对晚期慢性肾衰竭进展的潜在作用。采用多因素方差分析,分析了随访期间获得的平均动脉压(MAP)、抗高血压治疗(血压正常、传统抗高血压治疗、血管紧张素转换酶抑制剂[ACEI])、性别、肾病类型、年龄、体重指数和蛋白质摄入量的影响。平均动脉压与肌酐清除率的持续时间(r = -0.40,P < 0.0001)和斜率(δCcr;r = 0.32,P < 0.0001)显著且独立相关。平均动脉压和抗高血压治疗可预测持续时间变化的25%。性别、肾病类型和MAP能够预测δCcr变化的30%。按肾病类型分析结果时,MAP与肾小球肾炎的持续时间显著负相关(r = 0.29,P < 0.05),与肾血管硬化症和间质性肾炎的δCcr正相关(分别为r = 0.49,P < 0.05和r = 0.36,P < 0.01)。在每种肾病类型中,传统抗高血压治疗和ACEI对持续时间和斜率的影响总体相似。总之,血压水平是慢性肾衰竭进展的重要因素,但其影响在血压分布的极值时在肾血管硬化症和间质性肾炎中更为明显。(摘要截短至250字)